Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Dostarlimab in Combination With Cobolimab in Advanced Cervical Cancer

NCT06238635 is registered in ClinicalTrials.gov with Meghan Shea as lead sponsor.

NCT NCT06238635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06238635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Dostarlimab in Combination With Cobolimab in Advanced Cervical Cancer
Lead sponsor
Meghan Shea
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 11, 2024
Completion date
July 15, 2027
Enrollment
66 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cervical carcinoma, cervical cancer, metastatic cervical cancer, metastatic cervical carcinoma, recurrent cervical carcinoma